GeneDx files 11 IPR petitions against Myriad patents
Genetic testing company GeneDx has turned to the Patent Trial and Appeal Board to try and invalidate 11 of Myriad Genetics patents, in a move that underlines the increasing popularity of inter partes review proceedings with the pharmaceutical industry
Law firm Sterne Kessler Goldstein & Fox filed 11 petitions for inter partes review (IPR) on behalf of GeneDx, a subsidiary of BioReference Laboratories, aiming to nullify 11 patents owned, co-owned, or licensed by Myriad Genetics.
These patents have been asserted...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.